3'-hydroxy-benzoxazinorifamycin | 105396-63-2

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3'-hydroxy-benzoxazinorifamycin
• 英文别名: 3'-hydroxybenzoxazinorifamycin
• CAS: 105396-63-2
• 化学式: C₄₃H₄₈N₂O₁₃
• 分子量: 800.86
• InChiKey: FGNKQLLOMPHNTI-DAYGRRNASA-N

物化性质

• 沸点：
  971.1±65.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.65
• 重原子数：
  58.0
• 可旋转键数：
  2.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  224.18
• 氢给体数：
  5.0
• 氢受体数：
  14.0

反应信息

• 作为反应物：
  描述：

  N-异丁基哌嗪 、 3'-hydroxy-benzoxazinorifamycin 在 manganese(IV) oxide 作用下， 以 二甲基亚砜 为溶剂， 生成 Rifalazil
  参考文献：
  名称：

  Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins

  摘要：

  We report herein the preparation and anti-staphylococcal activity of a series of novel 11-deoxy-11-hydroxyiminorifamycins. Many of the compounds synthesized exhibit potent activity against wild-type Staphylococcus aureus with MICs equivalent to, or better than, rifamycin reference agents. In addition, some of the compounds retain potent activity against an intermediate rifamycin-resistant strain of Staphylococcus aureus. For instance, compound 5k exhibits an MIC of 0.12 mu g/mL against an intermediate rifamycin-resistant strain, while the rifamycin reference agents, rifampin and rifalazil, exhibit MICs of 16 mu g/mL and 2 mu g/mL, respectively, against the same strain. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.048
• 作为产物：
  描述：

  2-氨基间苯二酚 、 利福霉素 以 四氢呋喃 、 甲苯 为溶剂， 生成 3'-hydroxy-benzoxazinorifamycin
  参考文献：
  名称：

  Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins

  摘要：

  We report herein the preparation and anti-staphylococcal activity of a series of novel 11-deoxy-11-hydroxyiminorifamycins. Many of the compounds synthesized exhibit potent activity against wild-type Staphylococcus aureus with MICs equivalent to, or better than, rifamycin reference agents. In addition, some of the compounds retain potent activity against an intermediate rifamycin-resistant strain of Staphylococcus aureus. For instance, compound 5k exhibits an MIC of 0.12 mu g/mL against an intermediate rifamycin-resistant strain, while the rifamycin reference agents, rifampin and rifalazil, exhibit MICs of 16 mu g/mL and 2 mu g/mL, respectively, against the same strain. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.048

文献信息

• PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
  申请人：Rose Yannick Stephane

  公开号：US20110263534A1

  公开（公告）日：2011-10-27

  The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.

  本发明涉及磷酸化利福霉素以及制备和使用这类化合物的方法。这些化合物可用作预防和/或治疗骨骼和关节感染的抗生素，特别是用于预防和/或治疗骨髓炎。
• ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
  申请人：GENENTECH, INC.

  公开号：US20140356375A1

  公开（公告）日：2014-12-04

  The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

  本发明提供了抗壁葡聚糖酸抗体及其抗生素结合物，以及使用它们的方法。
• QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES
  申请人：Ding Charles Z.

  公开号：US20090143373A1

  公开（公告）日：2009-06-04

  The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.

  这些化合物包括取代利福霉素衍生物，其中喹诺酸药效基团与苯并噁唑利福霉素或螺环哌嗪利福霉素共价键合。 利福霉素衍生物可用作抗微生物剂，对多种人类和兽医革兰氏阳性和革兰氏阴性病原体有效。 发明化合物的优点在于，利福霉素和喹诺酮抗菌药效基团都与目标感兴趣的病原体具有匹配的药代动力学。同时将多种抗菌药效基团传递到目标病原体，最大程度地实现协同作用并最小化对给药抗生素的耐药性的发展的可能性。
• Nitroheteroaryl-containing rifamycin derivatives
  申请人：Ding Charles Z.

  公开号：US20080139577A1

  公开（公告）日：2008-06-12

  Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.

  本发明公开了替代利福霉素衍生物，其中硝基咪唑、硝基噻唑或硝基呋喃药效团与利福霉素共价键合，公开了使用该利福霉素衍生物的方法以及含有该利福霉素衍生物的制药组合物。还公开了合成这些替代利福霉素衍生物的方法。该利福霉素衍生物具有抗菌活性，并且在治疗细菌性疾病中对许多人类和兽医病原体有效。
• Siderophore conjugation with cleavable linkers boosts the potency of RNA polymerase inhibitors against multidrug-resistant<i>E. coli</i>
  作者：Carsten Peukert、Anna C. Vetter、Hazel L. S. Fuchs、Kirsten Harmrolfs、Bianka Karge、Marc Stadler、Mark Brönstrup

  DOI：10.1039/d2sc06850h

  日期：——

  RNA polymerase inhibitors against the bacteriumE. colibecome more potent when coupled to a siderophore enhancing cellular uptake, if the linker is cleaved inside the cell.

  针对大肠杆菌的 RNA 聚合酶抑制剂如果与一种能提高细胞吸收率的苷元结合，那么连接体在细胞内被裂解后会变得更有效。